Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jack William Lawler, Ph.D.

Co-Author

This page shows the publications co-authored by Jack Lawler and Peter Sadow.
Connection Strength

0.346
  1. Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment. J Natl Cancer Inst. 2014 Aug; 106(8).
    View in: PubMed
    Score: 0.146
  2. Corrigendum: Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells With BRAFV600E: New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment. Front Endocrinol (Lausanne). 2020; 11:596223.
    View in: PubMed
    Score: 0.056
  3. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFß1 Axis. Clin Cancer Res. 2018 12 01; 24(23):6078-6097.
    View in: PubMed
    Score: 0.048
  4. Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment. Front Endocrinol (Lausanne). 2013; 4:189.
    View in: PubMed
    Score: 0.035
  5. SCF(ß-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med. 2012 Jul 02; 209(7):1289-307.
    View in: PubMed
    Score: 0.032
  6. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist. 2011; 16(3):296-309.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.